v3.25.1
BUSINESS SEGMENT INFORMATION (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]      
Revenues $ 3,345.1 $ 3,176.6  
Operating income 326.0 321.3  
Amortization of Intangible Assets (69.6) (60.1)  
Net Restructuring Charges (6.4) (5.0)  
Goodwill and Intangible Asset Impairment 0.0 (2.5)  
Interest expense (56.0) (46.9)  
Investment income 6.5 2.9  
Equity method (loss) income, net (0.3) 0.1  
Other, net (1.0) 20.0  
Earnings before income taxes 275.2 297.4  
Asset Impairment Charges 0.0 (2.5)  
Operating Segments      
Segment Reporting Information [Line Items]      
Operating income 534.4 517.8  
Intersegment Eliminations      
Segment Reporting Information [Line Items]      
Revenues 5.8 14.0  
Corporate Segment [Member]      
Segment Reporting Information [Line Items]      
Operating income (132.4) (128.9)  
Diagnostics      
Segment Reporting Information [Line Items]      
Labor and Related Expense 1,123.6 1,055.7  
Supplies Expense 586.6 560.4  
Other Cost and Expense, Operating 430.2   $ 384.0
Diagnostics | Operating Segments      
Segment Reporting Information [Line Items]      
Revenues 2,629.6 2,479.7  
Operating income 427.5 417.9  
Depreciation 61.7 61.7  
Biopharma Laboratory Services      
Segment Reporting Information [Line Items]      
Labor and Related Expense 289.7 290.4  
Supplies Expense 111.1 103.5  
Freight 95.0 88.4  
Other Cost and Expense, Operating 90.0 97.5  
Biopharma Laboratory Services | Operating Segments      
Segment Reporting Information [Line Items]      
Revenues 721.3 710.9  
Operating income 106.9 99.9  
Depreciation $ 28.6 $ 31.2